Logo
  • Careers
  • Contact Us
  • Donate
  • Subscribe
Search
  • Home
  • About
    • About
    • Board of Directors
    • Senior Leadership
    • Financial Statements
    • Global Funding & Support
    • Our History: 1995-2021
  • Our Work
    • Our Work
    • Discovery & Research
      • Antibody Translational Research Program
      • Human Immunology Laboratory
      • IAVI Neutralizing Antibody Center
      • Vaccine Design and Development Laboratory
      • Clinical Research Centers
      • Clinical Research Standards
      • Observational Epidemiology Studies
      • IAVI in Africa
    • Translation & Product Development
    • Global Access to Scientific Innovations
    • ADVANCE
      • IAVI DataSpace
    • Advocacy & Community Engagement
      • CASPR
      • Tuberculosis R&D Advocacy
      • World Bank/Japan-supported
        Partnerships | 日本政府・世銀が支援するパートナーシップ
  • Our Science
    • Our Science
    • Pipeline
    • HIV Vaccines
    • bnAbs for HIV Prevention
    • Tuberculosis Vaccines
    • Emerging Infectious Diseases Vaccines
  • News & Resources
    • Latest NewsLatest News
    • Scientific Publications Scientific Publications
    • Press Releases
    • Features
    • IAVI Report
    • IAVI in the News
    • Fact Sheets & Publications
    • Vaccine Literacy Library
    • VOICES Newsletter
    • Multimedia
    • Media Contacts
    • Subscribe
  • Careers
  • Contact Us
  • Donate
  • Subscribe

Search

  • Home
  • About
    • About
    • Board of Directors
    • Senior Leadership
    • Financial Statements
    • Global Funding & Support
    • Our History: 1995-2021
  • Our Work
    • Our Work
    • Discovery & Research
    • Translation & Product Development
    • Global Access to Scientific Innovations
    • ADVANCE
    • Advocacy & Community Engagement
  • Our Science
    • Our Science
    • Pipeline
    • HIV Vaccines
    • bnAbs for HIV Prevention
    • Tuberculosis Vaccines
    • Emerging Infectious Diseases Vaccines
  • News & Resources
    • Latest NewsLatest News
    • Scientific Publications Scientific Publications
    • Press Releases
    • Features
    • IAVI Report
    • IAVI in the News
    • Fact Sheets & Publications
    • Vaccine Literacy Library
    • VOICES Newsletter
    • Multimedia
    • Media Contacts
    • Subscribe
  • Latest NewsLatest News
  • Scientific Publications Scientific Publications
  • Press Releases
  • Features
  • IAVI Report
  • IAVI in the News
  • Fact Sheets & Publications
  • Vaccine Literacy Library
  • VOICES Newsletter
  • Multimedia
  • Media Contacts
  • Subscribe

Scientific Publications

Filter By:

 

 
Filters

Mwau M, McMichael AJ, Hanke T

Design and validation of an enzyme-linked immunospot assay for use in clinical trials of candidate HIV vaccines. AIDS Res. Hum. Retroviruses 2002;18(9):611-8

Abstract & Topics (Click to display abstract, topics and IAVI Projects)    

The enzyme-linked immunosorbent (ELISPOT) assay, which enumerates peripheral blood mononuclear cells (PBMCs) releasing interferon gamma (IFN-gamma) on specific antigen stimulation, is becoming the assay of choice for evaluation of vaccine-induced cell-mediated immune responses in many clinical trials. A properly conducted trial requires the assays to be validated, especially should the trial lead to vaccine licensure. Here, the design and validation of an ELISPOT assay are described for use in clinical trials of candidate human immunodeficiency virus (HIV) vaccines, using a particular immunogen termed HIVA. This assay employs eight pools of 20 to 23 peptides each: seven pools are derived from the immunogen and one pool is derived from cytotoxic T cell epitopes of common human viruses serving as an internal positive control. The validation determined that first, the overall variation of a positive response of approximately 500 spot-forming units (SFU)/10(6) cells was 21%, while second, the average of 5 SFU/10(6) cells was detected for the seven HIVA-derived pools in HIV-uninfected individuals; third, a positive response to a peptide added to the assay pools was not occluded by the other pool peptides; fourth, the frequencies detected in fresh PBMCs were 2- to 3-fold higher compared with the same samples that had been cryopreserved; and finally, all seven HIV-derived pools induced IFN-gamma responses in PBMCs isolated from HIV-infected individuals. The limits of the validation of assays involving biological responses of living cells are discussed.

Topics: HIV Assay Development

Schultz AM, Bradac JAThe HIV vaccine pipeline, from preclinical to phase III. AIDS 2001;15 Suppl 5:S147-58

Abstract & Topics (Click to display abstract, topics and IAVI Projects)    

McMichael A, Hanke TThe quest for an AIDS vaccine: is the CD8+ T-cell approach feasible? Nat. Rev. Immunol. 2002;2(4):283-91

Abstract & Topics (Click to display abstract, topics and IAVI Projects)    

The rationale for developing anti-HIV vaccines that stimulate cytotoxic T-lymphocyte responses is given. We argue that such vaccines will work, provided that attention is paid to the development of memory T-cell responses that are strong and preferably activated. Furthermore, the vaccine should match the prevailing virus clade as closely as possible. Vaccines will have to stimulate a wide range of responses, but it is not clear how this can be achieved.

Wee EG, Patel S, McMichael AJ, Hanke TA DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses in rhesus macaques. J. Gen. Virol. 2002;83(Pt 1):75-80

Abstract & Topics (Click to display abstract, topics and IAVI Projects)    

The minimum requirement for candidate human immunodeficiency virus (HIV) vaccines to enter clinical evaluation in humans should be their demonstrable immunogenicity in non-human primates: induction of antibodies neutralizing primary HIV isolates or elicitation of broad T cell-mediated immune responses. Here, we showed in rhesus macaques that the very same vaccines that had entered clinical trials in Oxford and Nairobi, plasmid pTHr.HIVA DNA and recombinant modified vaccinia virus Ankara MVA.HIVA in a prime-boost protocol (Hanke & McMichael, Nature Medicine 6, 951-955, 2000), induced cellular immune responses specific for multiple HIV-derived epitopes. This was demonstrated by using the intracellular cytokine staining and ELISPOT assays detecting interferon-gamma and pools of peptides employed in the clinical studies. These results have both boosted our expectations for the performance of these vaccines in humans and increased our confidence about the choice of these assays as the primary readouts in the on-going human trials.

Wheeler C, Berkley SInitial lessons from public-private partnerships in drug and vaccine development. Bull. World Health Organ. 2001;79(8):728-34

Abstract & Topics (Click to display abstract, topics and IAVI Projects)    

In recent years, venture capital approaches have delivered impressive results in identifying and funding promising health discoveries and bringing them to market. This success has inspired public sector experiments with 'social venture capital' approaches to address the dearth of affordable treatment and prevention for diseases of the developing world. Employing the same focus on well-defined and measurable objectives, and the same type of connections to pool and deploy resources as their for-profit counterparts, social venture capitalists seek to use the tools and incentives of capitalism to solve one of its biggest failures: the lack of drugs and vaccines for diseases endemic to low-income populations. As part of a larger trend of partnerships emerging in health product donation and distribution, public-private partnerships for pharmaceutical development have led research and development (R&D) efforts to generate more accessible and efficacious products for diseases such as malaria, tuberculosis, and AIDS. In this article, three R&D-focused partnerships are explored: the International AIDS Vaccine Initiative; the Medicines for Malaria Venture; and the newly formed Global Alliance for TB Drug Development. The article highlights key elements essential to the success of these ventures.

Johnston MIHIV/AIDS Vaccine Development: Challenges, Progress and Future Directions. Rev. Med. Virol. 1996;6(3):123-140

Abstract & Topics (Click to display abstract, topics and IAVI Projects)    

Berkley S

HIV vaccine development for the world: an idea whose time has come? AIDS Res. Hum. Retroviruses 1998;14 Suppl 3:S191-6

Abstract & Topics (Click to display abstract, topics and IAVI Projects)    

Page 92 of 92

StartPrev838485868788...909192
Next
End

About

About

Board of Directors

Senior Leadership

Financial Statements

Global Funding & Support

Our History: 1995-2021

Our Work

Our Work

Discovery & Research

Translation & Product Development

Global Access to Scientific Innovations

ADVANCE

Advocacy & Community Engagement

Our Science

Our Science

Pipeline

HIV Vaccines

bnAbs for HIV Prevention

Tuberculosis Vaccines

Emerging Infectious Diseases Vaccines

News & Resources

Latest NewsLatest News

Scientific Publications Scientific Publications

Press Releases

Features

IAVI Report

IAVI in the News

Fact Sheets & Publications

Vaccine Literacy Library

VOICES Newsletter

Multimedia

Media Contacts

Subscribe

icon iaviIAVI guidestar platinum seal 2021 IAVI Charity Navigator 2021

Accessibility

Compliance/RFPs

Contact IAVI

Privacy Policy

Site Map

Supplier Diversity

Terms of Use

©2023 International AIDS Vaccine Initiative. International AIDS Vaccine Initiative®, IAVI®, and the IAVI logo® are registered trademarks of the International AIDS Vaccine Initiative, Inc.